Presented at the ASCP Annual Meeting May 29-31,2020 Virtual Conference
Depression and psychosis clinical trials share a crucial commonality of perpetually and alarmingly high placebo and nocebo responses. At ASCP in May 2019, Cohen, et al. presented data indicating that the Placebo-Control Reminder Script (PCRS) significantly reduced the placebo effect among subjects in a major depressive episode (MDE). Since then, the same study design, was applied among subjects with a psychotic disorder. This poster presents these data and the combined results from both populations.